KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Investment Securities (2016 - 2020)

Esperion Therapeutics filings provide 4 years of Gains from Investment Securities readings, the most recent being $134945.0 for Q2 2020.

  • On a quarterly basis, Gains from Investment Securities fell 97.46% to $134945.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $134945.0, a 97.46% decrease, with the full-year FY2025 number at $612000.0, changed N/A from a year prior.
  • Gains from Investment Securities hit $134945.0 in Q2 2020 for Esperion Therapeutics, down from $4.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.3 million in Q2 2019 to a low of $134945.0 in Q2 2020.
  • Median Gains from Investment Securities over the past 4 years was $4.5 million (2018), compared with a mean of $3.5 million.
  • The widest YoY moves for Gains from Investment Securities: up 3361.97% in 2020, down 97.46% in 2020.
  • Esperion Therapeutics' Gains from Investment Securities stood at $4.2 million in 2017, then grew by 27.52% to $5.3 million in 2018, then dropped by 11.8% to $4.7 million in 2019, then tumbled by 97.12% to $134945.0 in 2020.
  • The last three reported values for Gains from Investment Securities were $134945.0 (Q2 2020), $4.8 million (Q1 2020), and $4.7 million (Q4 2019) per Business Quant data.